Revolution Medicines doses first patient in Phase 1/1b trial of RMC-9805

Revolution Medicines announced the first patient was dosed in its Phase 1/1b monotherapy clinical trial of RMC-9805, an oral, covalent, mutant-selective KRASG12D Inhibitor designed to treat patients with cancers driven by the KRASG12D mutation. “The initiation of patient dosing with RMC-9805 marks a major milestone for Revolution Medicines as its third oral RAS Inhibitor to begin clinical evaluation,” said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. “We are now sudying in the clinic three highly innovative RAS(ON) Inhibitors derived from our pioneering tri-complex inhibitor platform that we believe have complementary profiles – RMC-6236 for patients with cancers caused by a wide range of RAS mutations, and the mutant-selective compounds RMC-629 and RMC-9805 for patients with cancers harboring selected mutations. With this strong clinical portfolio, as well as a rich collection of additional mutant-selective drug candidates and research-stage assets, we believe our pipeline has the potential to change the standard of care for patients living with a wide range of RAS-addicted cancers including NSCLC, pancreatic cancers and colorectal cancers.”